Accolade Q1 2024 Earnings Report $3.40 -0.05 (-1.45%) (As of 05:10 PM ET) Earnings HistoryForecast Accolade EPS ResultsActual EPS-$0.52Consensus EPS -$0.62Beat/MissBeat by +$0.10One Year Ago EPS-$0.62Accolade Revenue ResultsActual Revenue$93.20 millionExpected Revenue$90.82 millionBeat/MissBeat by +$2.38 millionYoY Revenue Growth+9.00%Accolade Announcement DetailsQuarterQ1 2024Date6/29/2023TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseACCD Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Wall St. Icon: “If you wait on this, it will already be too late” (Ad)If you have a significant amount of money in the stock market right now — or if you're sitting on the sidelines waiting to make a move — you DO NOT want to miss my latest research.Go here now to see my urgent warning Accolade Earnings HeadlinesReviewing Sezzle (NASDAQ:SEZL) & Accolade (NASDAQ:ACCD)December 19, 2024 | americanbankingnews.comMorgan Stanley Has Lowered Expectations for Accolade (NASDAQ:ACCD) Stock PriceDecember 18, 2024 | americanbankingnews.comWall St. Icon: “If you wait on this, it will already be too late”If you have a significant amount of money in the stock market right now — or if you're sitting on the sidelines waiting to make a move — you DO NOT want to miss my latest research.December 24, 2024 | InvestorPlace (Ad)Accolade price target lowered to $5 from $6 at Morgan StanleyDecember 18, 2024 | markets.businessinsider.comBreaking Down Accolade: 8 Analysts Share Their ViewsDecember 18, 2024 | benzinga.comAccolade to Announce Fiscal Third Quarter 2025 Financial ResultsDecember 16, 2024 | globenewswire.comSee More Accolade Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Accolade? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Accolade and other key companies, straight to your email. Email Address About AccoladeAccolade (NASDAQ:ACCD), together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington.View Accolade ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
